Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION JPMA Launches Website Listing R&D Policies of Members to Help Foster Innovation Ecosystem
April 9, 2024
-
BUSINESS GSK Japan Shooting for 80% Goal for Paid Paternity Leave in 2024
April 8, 2024
-
BUSINESS Kyowa Kirin Hopes Amgen-Partnered Eczema Drug to Rival or Even Eclipse Crysvita in Sales: CEO
April 5, 2024
-
ORGANIZATION PhRMA Hails 2024 Reform, but Says Full Picture Unchanged as 50% of Patented Meds Still Face Cuts
April 4, 2024
-
REGULATORY Opposition Party Head Calls for Rethink of Public Health Coverage in Japan
April 3, 2024
-
COMMENTARY With Honebuto 2024 Looming, Now Is the Time to Revisit Social Security Spending
April 2, 2024
-
BUSINESS New Ono Chief Eager to Go Solo in US, Europe; BTK Med 1st Shield against Opdivo Patent Cliff
April 1, 2024
-
BUSINESS Parexel Helping Japan Address Drug Loss with “Ethnobridging” Studies, PI Still a Hurdle
March 29, 2024
-
REGULATORY MHLW Generic Panel Outlines Plan to Drive Industry Revamp within Specific Time Frame
March 28, 2024
-
REGULATORY Japan Approves Piasky, Beyfortus, Broader Use for Abrysvo, and Lot More
March 27, 2024
-
ORGANIZATION Backed by 12 Pharmas, US Nonprofit’s Cloud Platform Now Up and Running to Streamline Regulatory Submissions
March 26, 2024
-
REGULATORY Chuikyo Agrees to Exempt PD-1/PD-L1, JAK Classes from Spillover Re-Pricing
March 25, 2024
-
REGULATORY Xocova’s Price to Remain Intact after Full Approval, No Change in Clinical Positioning
March 25, 2024
-
REGULATORY Pharma Regulation Panel Wraps Up Debate, Report to Be Finalized Soon
March 22, 2024
-
REGULATORY Japan Resumes Debate on Rx-to-OTC Switch of PPIs after Over 5 Years
March 22, 2024
-
BUSINESS Will Kyowa Kirin’s Eye Drops for nAMD Replace Intraocular Injections? PII Now Underway
March 21, 2024
-
BUSINESS Meiji’s Bivalent COVID Jab Hits Primary Goal in PIII Omicron Trial; New Strains Eyed
March 21, 2024
-
REGULATORY Japan Mulls Simplifying Drug Delisting Process to Help Ensure Stable Supplies
March 19, 2024
-
BUSINESS FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products
March 18, 2024
-
BUSINESS Sumitomo Offloads Entire Ulotaront Rights to Otsuka for Strategic Priorities
March 18, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…